1. Home
  2. IMNM vs HSAI Comparison

IMNM vs HSAI Comparison

Compare IMNM & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.12

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo Hesai Group each ADS represents one Class B ordinary share

HSAI

Hesai Group each ADS represents one Class B ordinary share

HOLD

Current Price

$15.01

Market Cap

2.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
HSAI
Founded
2006
2014
Country
United States
China
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.7B
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
IMNM
HSAI
Price
$22.12
$15.01
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
4
Target Price
$32.80
$31.58
AVG Volume (30 Days)
1.7M
2.0M
Earning Date
05-08-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
51.40
N/A
EPS
N/A
N/A
Revenue
$6,941,000.00
N/A
Revenue This Year
N/A
$46.29
Revenue Next Year
$1,127.34
$41.32
P/E Ratio
N/A
$61.18
Revenue Growth
N/A
N/A
52 Week Low
$8.67
$14.40
52 Week High
$27.65
$30.85

Technical Indicators

Market Signals
Indicator
IMNM
HSAI
Relative Strength Index (RSI) 52.69 37.87
Support Level $19.28 $14.55
Resistance Level $23.25 $24.30
Average True Range (ATR) 1.36 0.90
MACD -0.03 0.02
Stochastic Oscillator 45.98 7.74

Price Performance

Historical Comparison
IMNM
HSAI

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About HSAI Hesai Group each ADS represents one Class B ordinary share

Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.

Share on Social Networks: